Impact BioMedical Announces 1 For 12.62 Reverse Stock Split To Pursue Completion Of Merger With Zoar

IBO•2026-09-11

Reverse stock split approved ahead of Zoar merger

Impact Biomedical Inc. (NYSE American: IBO) announced a 1-for-12.62 reverse stock split to pursue completion of its merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.).

The reverse stock split is effective September 23, 2026.

Impact BioMedical Announces 1 For 12.62 Reverse Stock Split To Pursue Completion Of Merger With Zoar

Reverse stock split approved ahead of Zoar merger

Related News

Stellantis signs memorandum of understanding with Roshel for potential Canadian factory sale

Kite Realty Group presents at BofA Securities Global Real Estate Conference

Fusion Fuel Green offer up to 4,993,249 Class A ordinary shares by selling shareholders - SEC filing

Iraq orders investigation into Saudi East-West pipeline attack

Arteris grants CFO Saurabh Sinha $4.7 million in inducement RSUs, PSUs